Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enteric-coated mycophenolate sodium plus reduced-dose steroids in IgA nephropathy with active proliferative lesions
ChiCTR2200060990Phase 4Recruiting
- Sponsor
- The First Affiliated Hospital of USTC
- Start
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of mycophenolate sodium in IgA nephropathy (IgAN) (2 arms), sponsored by The First Affiliated Hospital of USTC. Primary endpoint: Complete remission rate. Started Jun 2022; status: recruiting.
02
Drugs
mycophenolate sodium
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on ChiCTR2200060990.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200060990.